Any current/future new fundraising through debt or equity?

No fresh loans were taken during the quarter; only normal maturities and working capital limits were used. There was no loan maturity during the quarter other than normal working capital repayments. The company currently does not indicate any immediate plans for raising new debt. Management focus is on investing for growth rather than raising capital through buybacks or fundraising. Capital expenditure for FY2020 is budgeted around 120 Crores, including asset investments and some possible intangible capitalizations. No mention of any planned equity fundraising or share buyback initiatives at t

Any current/future capex/capital investment/strategic investment?

TAKE Solutions expects a total Capex of about 120 Crores for the fiscal year, including investments in tangible assets such as facilities, replacements, and refurbishments. In Q1 FY2020, the company invested around 20 to 22 Crores in Capex. Intangible asset investments (including IP) have been muted in the past two years; however, ongoing work might lead to some capitalization during the year. Future investments and Capex will depend on growth and order book levels. The company is investing in capacity creation to support revenue growth, currently at about 55% utilization, expecting improvemen

Future growth expectations in sales/revenue/volumes?

TAKE Solutions closed the previous year at $292 million in revenue. For FY2020, they expect to reach closer to $370-380 million, possibly surpassing this. The company targets a long-term vision of reaching $0.5 billion in topline revenue. Growth is currently above industry standards, though the high historic CQGR of around 8% may not be sustained indefinitely. Recent acquisitions (KAI Research and DataCeutics) are progressing well, expected to contribute increasingly to consolidated growth. The company is pursuing larger deals, with some potential contracts valued above $10 million, and up to

Future growth expectations in earnings/operating earnings/profits/EPS?

TAKE Solutions expects steady business growth; revenue projections aim to reach around $370-380 million for the current year, closing a gap toward a longer-term $0.5 billion topline target. Growth rate may moderate from previous ~8% CQGR but will remain above industry standards. Margin improvement is anticipated once recent acquisitions (KAI Research and DataCeutics) scale up and offshoring initiatives take effect; currently margins are flattish due to blended lower margins and increased expenses. EBITDA margin blended at 18.8% for Q1 FY2020, expected to stabilize. Operating cash flow to EBITD

Current/ Expected Orderbook/ Pending Orders?

The life sciences order book stood at $269.5 million, reflecting a 10% quarter-on-quarter and 42% year-on-year growth. Approximately 55% of the order book is attributed to clinical research, with the balance in pharmacovigilance (PY) and regulatory services. The quarter saw two deals exceeding $10 million awarded, one renewal and one new client, both extending into 2022. There is strong RFP activity, particularly at KAI Research, expected to lead to a robust order book for FY2021. The company is actively pursuing around 10 deals in the RFP stage valued over $10 million. The firm's strategy in

Take SolutionsQ2 FY20Healthcare Services

Take Solutions Q2 FY20 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹23.7P/E: 77.1Market Cap: ₹329 CrSector: Healthcare Services

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

N/A

Order

Yes

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 2

→TAKE Solutions closed the previous year at $292 million in revenue.
→For FY2020, they expect to reach closer to $370-380 million, possibly surpassing this.
→The company targets a long-term vision of reaching $0.5 billion in topline revenue.
→Growth is currently above industry standards, though the high historic CQGR of around 8% may not be sustained indefinitely.
→Recent acquisitions (KAI Research and DataCeutics) are progressing well, expected to contribute increasingly to consolidated growth.
→The company is pursuing larger deals, with some potential contracts valued above $10 million, and up to $25 million.
→Expansion of multi-country clinical trials is driving growth opportunities.
→Capacity utilization is currently around 55%, and as it improves, revenue growth and cash flow generation are expected to accelerate further.

Margin guidance

Category 3

→TAKE Solutions expects steady business growth; revenue projections aim to reach around $370-380 million for the current year, closing a gap toward a longer-term $0.5 billion topline target.
→Growth rate may moderate from previous ~8% CQGR but will remain above industry standards.
→Margin improvement is anticipated once recent acquisitions (KAI Research and DataCeutics) scale up and offshoring initiatives take effect; currently margins are flattish due to blended lower margins and increased expenses.
→EBITDA margin blended at 18.8% for Q1 FY2020, expected to stabilize.
→Operating cash flow to EBITDA ratio is projected to improve over the next two years as capacity utilization increases from ~55%, enhancing cash generation.
→New large deals (several > $10 million) and a healthy diversified order book (> $269 million) support growth visibility.
→Management focuses on reinvestment and growth rather than buybacks at present.

3 more insights locked — sign up free to unlock

Fundraise plans

→No fresh loans were taken during the quarter; only normal maturities and working capital limits were used.
→There was no loan maturity during the quarter other than normal working capital repayments.
→The company currently does not indicate any immediate plans for raising new debt.
→Management focus is on investing for growth rather than raising capital through buybacks or fundraising.
→Capital expenditure for FY2020 is budgeted around 120 Crores, including asset investments and some possible intangible capitalizations.
→No mention of any planned equity fundraising or share buyback initiatives at this time; management prefers investing in business growth.

Order book

Yes

→The life sciences order book stood at $269.5 million, reflecting a 10% quarter-on-quarter and 42% year-on-year growth.
→Approximately 55% of the order book is attributed to clinical research, with the balance in pharmacovigilance (PY) and regulatory services.
→The quarter saw two deals exceeding $10 million awarded, one renewal and one new client, both extending into 2022.
→There is strong RFP activity, particularly at KAI Research, expected to lead to a robust order book for FY2021.
→The company is actively pursuing around 10 deals in the RFP stage valued over $10 million.
→The firm's strategy includes growth through multi-country trials and innovative technology usage to drive order intake and execution.

Capex plans

Yes

→TAKE Solutions expects a total Capex of about 120 Crores for the fiscal year, including investments in tangible assets such as facilities, replacements, and refurbishments.
→In Q1 FY2020, the company invested around 20 to 22 Crores in Capex.
→Intangible asset investments (including IP) have been muted in the past two years; however, ongoing work might lead to some capitalization during the year.
→Future investments and Capex will depend on growth and order book levels.
→The company is investing in capacity creation to support revenue growth, currently at about 55% utilization, expecting improvements over the next two years.
→Additional Capex is also targeted towards offshoring initiatives in newly acquired entities to improve margins.

How does Take Solutions rank vs peers in Healthcare Services?

Pro feature

1Take Solutions

Rev 2Mar 3

See full Healthcare Services sector rankings

Want more stocks like Take Solutions?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio